Horn Lars-Christian, Hentschel Bettina, Bilek Karl, Richter Christine E, Einenkel Jens, Leo Cornelia
Institute of Pathology, Division of Gynecologic Pathology, University of Leipzig, Germany.
Ann Diagn Pathol. 2006 Jun;10(3):140-3. doi: 10.1016/j.anndiagpath.2005.07.019.
Small cell neuroendocrine carcinomas sometimes represent a non-small cell component. Because of infection with the high-risk human papillomavirus of small cell carcinomas (SmCCs), several host cell regulatory proteins are altered, thus causing altered proliferative activity. Knowledge regarding the prognostic impact of focal neuroendocrine differentiation in mixed SmCCs and the value of proliferative activity in these tumors is very limited. Small cell carcinomas were selected for immunohistochemical staining with neuroendocrine markers and Ki-67. In cases with mixed tumors, the percentage of the SmCC component was calculated and correlated with survival. Of 677 tumors, 9 (1.3%) were classified as SmCCs after Grimelius staining (8/9 positive tumors) and immunohistochemical reaction against neuron-specific enolase, chromogranin A, synaptophysin (7/9 positive tumors), and CD56 (8/9 positive tumors); all specimens were positive for at least 2 of these. CD99 staining was completely negative. Two thirds of the SmCCs showed non-small cell differentiation. Four patients died of the tumor after a median time of 36.7 months (range, 15-56 months). Even an SmCC component of 17% was associated with a fatal course. Small cell carcinoma represented a significantly lower proliferation (Ki-67 labeling index) than did the non-small cell component in the same tumor (12.8% vs 70.8%; P < .001). Even a small SmCC component in mixed carcinomas of the uterine cervix was associated with adverse outcome. Proliferative activity, determined by Ki-67 labeling index, is of no prognostic value.
小细胞神经内分泌癌有时表现出非小细胞成分。由于小细胞癌(SmCCs)感染高危人乳头瘤病毒,几种宿主细胞调节蛋白发生改变,从而导致增殖活性改变。关于混合性SmCCs中局灶性神经内分泌分化的预后影响以及这些肿瘤中增殖活性的价值的知识非常有限。选择小细胞癌进行神经内分泌标志物和Ki-67的免疫组织化学染色。在混合性肿瘤病例中,计算SmCC成分的百分比并与生存率相关联。在677例肿瘤中,9例(1.3%)经 Grimelius 染色(8/9例阳性肿瘤)以及针对神经元特异性烯醇化酶、嗜铬粒蛋白A、突触素(7/9例阳性肿瘤)和CD56(8/9例阳性肿瘤)的免疫组织化学反应后被分类为SmCCs;所有标本至少对其中2种呈阳性。CD99染色完全阴性。三分之二的SmCCs表现出非小细胞分化。4例患者在中位时间36.7个月(范围15 - 56个月)后死于肿瘤。即使SmCC成分仅为17%也与致命病程相关。在同一肿瘤中,小细胞癌的增殖(Ki-67标记指数)明显低于非小细胞成分(12.8%对70.8%;P < .001)。即使是子宫颈混合癌中的小SmCC成分也与不良预后相关。由Ki-67标记指数确定的增殖活性无预后价值。